- Home
- LTC vs NRIX Comparison
LTC vs NRIX Comparison
Compare LTC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTC | NRIX |
|---|---|---|
| Founded | 1992 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1992 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LTC | NRIX |
|---|---|---|
| Price | $34.50 | $18.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $39.00 | $27.46 |
| AVG Volume (30 Days) | 399.2K | ★ 2.0M |
| Earning Date | 11-04-2025 | 01-27-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $226,987,000.00 | $83,687,000.00 |
| Revenue This Year | N/A | $58.38 |
| Revenue Next Year | $22.49 | N/A |
| P/E Ratio | $47.84 | ★ N/A |
| Revenue Growth | 14.23 | ★ 48.32 |
| 52 Week Low | $31.70 | $8.18 |
| 52 Week High | $37.25 | $22.50 |
Technical Indicators
Market Signals| Indicator | LTC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 58.54 |
| Support Level | $34.28 | $19.02 |
| Resistance Level | $35.28 | $22.50 |
| Average True Range (ATR) | 0.55 | 1.28 |
| MACD | -0.13 | -0.24 |
| Stochastic Oscillator | 10.87 | 33.33 |
Price Performance
Historical ComparisonAbout LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.